ABBV · AbbVie · Q2 FY2026
AbbVie appoints Dr. John M. Carethers to its board
AbbVie expanded its board from twelve to thirteen directors on Oct 14, 2026 and appointed Dr. John M. Carethers a Class II director, according to a Form 8-K filed Oct 15, 2026.
- Published
- Oct 20, 2026
- Event
- Oct 14, 2026
- Quarter ended
- Jun 30, 2026
- Data as of
- Oct 15, 2026
Published becauseA director appointment dated Oct 14, 2026 was disclosed in a Form 8-K filed Oct 15, 2026.
The Blockhaven read
AbbVie appointed Dr. John M. Carethers to its board on October 14, 2026, according to a Form 8-K filed October 15. The board grew from twelve to thirteen directors, and Dr. Carethers joined as a Class II director and a member of the Public Policy and Sustainability Committee. The filing describes him as Vice Chancellor for Health Sciences at the University of California San Diego and a former director of Avantor, and says the board determined he is independent under New York Stock Exchange standards. He will be paid as an independent director under the arrangements AbbVie describes in an earlier 10-Q exhibit. AbbVie's latest reported quarter, Q2 FY2026, ended Jun 30, 2026, before this event, so its figures cannot show any effect.
Latest reported quarter
13-week quarter · Earnings release filed Jul 31, 2026
Shown for context: the quarter most recently reported when this note was written, on Jul 31, 2026. It is not the subject of this note.
RevenueGAAP
- Latest
- $17 billion
- Year ago
- $15.4 billion
- Change
- +10.2% (Up year over year)
Operating incomeGAAP
- Latest
- $6.43 billion
- Year ago
- $4.89 billion
- Change
- +31.4% (Up year over year)
Net incomeGAAP
- Latest
- $3.61 billion
- Year ago
- $938 million
- Change
- +285.2% (Up year over year)
Diluted EPSGAAP
- Latest
- $2.03
- Year ago
- $0.52
- Change
- +290.4% (Up year over year)
Operating margin (GAAP)Derived
- Latest
- 37.9%
- Year ago
- 31.7%
- Change
- +613 bp (Up year over year)
| Measure | Basis | Latest quarter | Year ago | Change |
|---|---|---|---|---|
| Revenue | GAAP | $17 billion | $15.4 billion | +10.2% (Up year over year) |
| Operating income | GAAP | $6.43 billion | $4.89 billion | +31.4% (Up year over year) |
| Net income | GAAP | $3.61 billion | $938 million | +285.2% (Up year over year) |
| Diluted EPS | GAAP | $2.03 | $0.52 | +290.4% (Up year over year) |
| Operating margin (GAAP) | Derived | 37.9% | 31.7% | +613 bp (Up year over year) |
Revenue growth +10.2% against +12.4% in the prior quarter (year over year, GAAP).
Trend: Mixed. Revenue growth slowed, operating margin widened and GAAP operating income improved.
GAAP unless labelled. Non-GAAP and company-defined measures are labelled.
What changed
- AbbVie expanded its board from twelve to thirteen directors on Oct 14, 2026 and appointed Dr. John M. Carethers as a Class II director.
- Dr. Carethers joins the Public Policy and Sustainability Committee; the board determined he is independent under New York Stock Exchange standards.
Key facts
- Role
- Class II director as reported
- Action
- Appointment; board expanded to 13 as reported
- Appointment date
- October 14, 2026 as reported
- Committee
- Public Policy and Sustainability as reported
Why it matters
A change to the board: AbbVie added a thirteenth seat rather than replacing a director, and the new director is independent under the exchange's standards.
The appointment falls in AbbVie's fourth quarter of 2026; the latest reported quarter, Q2 FY2026, ended before it.
What to watch
- AbbVie's next proxy statement, which reports each director's committee roles and pay.
- Later filings that change the board's or management's composition (Form 8-K, Item 5.02).
Data and sources
The appointment comes from AbbVie's Form 8-K (Item 5.02) filed Oct 15, 2026. Quarter figures come from the company's SEC filings (Form 10-Q for the quarter ended Jun 30, 2026). GAAP figures are labelled as such. Blockhaven used no outside forecasts.
Descriptive company facts. Not investment advice, a rating or a recommendation.